Rec'(CT/PTC 21 FEB 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Campochiaro et al.

Appl. No.:

10/526,127

Conf. No.:

2577

Filed:

28 February 2005

Title:

OCULAR GENE THERAPY

Art Unit:

Unassigned

Examiner:

Unassigned

Docket No.:

116566-002

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form be made during the course of examination of the above-identified application for United States patent. The references below were cited in the Search Report in the corresponding PCT application. A copy of the Search Report is enclosed.

U.S. PATENT DOCUMENTS

Document No.

Date

Inventor

6,267,954

7/31/01

Abitbol et al.

FOREIGN PATENT DOCUMENTS

Document No.

Date

Country

WO 0193897

12/13/01

WIPO

WO 0230982

4/18/02

WIPO

OTHER DOCUMENTS

Mori, Keisuke et al., "Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin," American Journal of Pathology, Vol. 159, No. 1, July 2001, pp. 313-320.

Ohno-Matsui, Kyoko et al., "Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment," American Journal of Pathology, Vol. 160, No. 2, February 2002, pp. 711-719.

1

Ozaki, H. et al., "Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization," *American Journal of Pathology*, Vol. 156, No. 2, February 2000, pp. 697-707.

Takahashi, Kyoichi et al., "Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment," *FASEB Journal*, Vol. 17, No. 8, May 2003, pp. 896-898.

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOXD & LLOYD LLC

Dean H. Nakamura

Reg. No. 33,981 P.O. Box 1135

CL'---- TIL--'- COC

Chicago, Illinois 60690-1135

Phone: (202) 955-6851

Dated: 15 February 2006

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Atty Docket No.	Application No.			
116566-002	10/526,127			
Applicant				
Campochiaro et al.				
Filing Date	Group			
28 February 2005	Unassigned			

PTO Form 1449

U.S. PATENT DOCUMENTS							
Examiner's Initials	-	Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
		6,267,954	7/31/01	Abitbol et al.			
		-					
				_			

FOREIGN PATENT DOCUMENTS							
Examiner's	Document	Publication				Trans	lation
Initials	Number	Date	Country	Class	Subclass	Yes	No
	WO 0193897	12/13/01	WIPO				-
	WO 0230982	4/18/02	WIPO				
		·					
				•	,		

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Mori, Keisuke et al., "Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin," <i>American Journal of Pathology</i> , Vol. 159, No. 1, July 2001, pp. 313-320.
	Ohno-Matsui, Kyoko et al., "Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment," <i>American Journal of Pathology</i> , Vol. 160, No. 2, February 2002, pp. 711-719.
	Ozaki, H. et al., "Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization," <i>American Journal of Pathology</i> , Vol. 156, No. 2, February 2000, pp. 697-707.
	Takahashi, Kyoichi et al., "Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment," <i>FASEB Journal</i> , Vol. 17, No. 8, May 2003, pp. 896-898.

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not	citation is in conformance with MPEP Section 609;
Draw line through citation if not in conformance and no	t considered. Include copy of this form with next
communication to applicant.	· · ·